S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:INMD

InMode - INMD Stock Forecast, Price & News

$36.98
+0.94 (+2.61%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$35.70
$37.30
50-Day Range
$21.45
$38.27
52-Week Range
$20.60
$99.27
Volume
1.30 million shs
Average Volume
2.01 million shs
Market Capitalization
$3.08 billion
P/E Ratio
18.40
Dividend Yield
N/A
Price Target
$55.60

InMode MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
50.4% Upside
$55.60 Price Target
Short Interest
Healthy
8.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.81mentions of InMode in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

396th out of 1,117 stocks

Electromedical Equipment Industry

9th out of 24 stocks

INMD stock logo

About InMode (NASDAQ:INMD) Stock

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on INMD shares. TheStreet raised InMode from a "d+" rating to a "b-" rating in a report on Tuesday. Needham & Company LLC increased their target price on shares of InMode from $58.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, July 29th. Robert W. Baird upped their price target on shares of InMode from $44.00 to $53.00 in a research report on Friday, July 29th. Canaccord Genuity Group decreased their price objective on shares of InMode from $50.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday, June 30th. Finally, Canaccord Genuity Group lowered their target price on shares of InMode from $50.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday, June 30th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, InMode has a consensus rating of "Buy" and a consensus price target of $63.00.

InMode Stock Up 2.6 %

Shares of INMD Stock opened at $36.98 on Friday. The company's fifty day simple moving average is $27.27 and its two-hundred day simple moving average is $32.43. InMode has a 52 week low of $20.60 and a 52 week high of $99.27. The stock has a market cap of $3.08 billion, a P/E ratio of 18.40 and a beta of 2.32.

InMode (NASDAQ:INMD - Get Rating) last issued its earnings results on Thursday, July 28th. The healthcare company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.08. InMode had a return on equity of 41.50% and a net margin of 42.66%. The firm had revenue of $113.55 million for the quarter, compared to analysts' expectations of $103.00 million. During the same period in the previous year, the firm posted $1.02 earnings per share. The business's revenue was up 30.0% compared to the same quarter last year.

Receive INMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMode and its competitors with MarketBeat's FREE daily newsletter.

INMD Stock News Headlines

InMode (NASDAQ:INMD) Lifted to "B-" at TheStreet
Jim Cramer: 'I Am No Longer A Huge Crypto Guy'
Here's Why InMode Stock Jumped 48% in July
InMode (NASDAQ:INMD) Price Target Raised to $60.00
Here's Why InMode Stock Surged Today
See More Headlines
Receive INMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMode and its competitors with MarketBeat's FREE daily newsletter.

INMD Company Calendar

Last Earnings
7/28/2022
Today
8/13/2022
Next Earnings (Estimated)
10/25/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INMD
Fax
N/A
Employees
362
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$55.60
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+50.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$164.97 million
Pretax Margin
45.25%

Debt

Sales & Book Value

Annual Sales
$357.57 million
Cash Flow
$2.03 per share
Book Value
$5.44 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.08 billion
Optionable
Not Optionable
Beta
2.32

Social Links


Key Executives

  • Mr. Yair Malca (Age 44)
    Chief Financial Officer
    Comp: $525k
  • Mr. Alon Yaari
    VP of Operations
  • Ms. Nava Tal-Launer
    Chief Information Officer
  • Mr. Shakil Lakhani (Age 39)
    Pres of North America
    Comp: $2.67M
  • Dr. Spero Theodorou M.D. (Age 50)
    Chief Medical Officer
    Comp: $1.84M
  • Mr. Moshe Mizrahy (Age 69)
    Chairman & CEO
  • Dr. Michael Kreindel (Age 54)
    CTO & Director













INMD Stock - Frequently Asked Questions

Should I buy or sell InMode stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INMD shares.
View INMD analyst ratings
or view top-rated stocks.

What is InMode's stock price forecast for 2022?

5 brokers have issued twelve-month price objectives for InMode's stock. Their INMD share price forecasts range from $40.00 to $85.00. On average, they anticipate the company's share price to reach $55.60 in the next twelve months. This suggests a possible upside of 50.4% from the stock's current price.
View analysts price targets for INMD
or view top-rated stocks among Wall Street analysts.

How have INMD shares performed in 2022?

InMode's stock was trading at $70.58 at the beginning of 2022. Since then, INMD shares have decreased by 47.6% and is now trading at $36.98.
View the best growth stocks for 2022 here
.

When is InMode's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 25th 2022.
View our INMD earnings forecast
.

How were InMode's earnings last quarter?

InMode Ltd. (NASDAQ:INMD) issued its quarterly earnings results on Thursday, July, 28th. The healthcare company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.51 by $0.08. The healthcare company earned $113.55 million during the quarter, compared to analyst estimates of $103 million. InMode had a net margin of 42.66% and a trailing twelve-month return on equity of 41.50%. The business's quarterly revenue was up 30.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.02 earnings per share.

When did InMode's stock split?

InMode shares split before market open on Thursday, September 30th 2021. The 2-1 split was announced on Friday, September 17th 2021. The newly issued shares were issued to shareholders after the closing bell on Monday, September 27th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has InMode issued on next quarter's earnings?

InMode updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of $2.11-$2.16 for the period, compared to the consensus earnings per share estimate of $2.08. The company issued revenue guidance of $425.00 million-$435.00 million, compared to the consensus revenue estimate of $425.36 million.

What is Moshe Mizrahy's approval rating as InMode's CEO?

1 employees have rated InMode Chief Executive Officer Moshe Mizrahy on Glassdoor.com. Moshe Mizrahy has an approval rating of 100% among the company's employees. This puts Moshe Mizrahy in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of InMode own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), DocuSign (DOCU) and PayPal (PYPL).

When did InMode IPO?

(INMD) raised $75 million in an initial public offering (IPO) on Thursday, August 8th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity acted as the underwriters for the IPO and Baird was co-manager.

What is InMode's stock symbol?

InMode trades on the NASDAQ under the ticker symbol "INMD."

Who are InMode's major shareholders?

InMode's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (3.72%), William Blair Investment Management LLC (2.27%), Noked Israel Ltd (1.87%), Meitav Dash Investments Ltd. (1.72%), Harel Insurance Investments & Financial Services Ltd. (0.80%) and Ibex Investors LLC (0.78%).

How do I buy shares of InMode?

Shares of INMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InMode's stock price today?

One share of INMD stock can currently be purchased for approximately $36.98.

How much money does InMode make?

InMode (NASDAQ:INMD) has a market capitalization of $3.08 billion and generates $357.57 million in revenue each year. The healthcare company earns $164.97 million in net income (profit) each year or $2.01 on an earnings per share basis.

How many employees does InMode have?

The company employs 362 workers across the globe.

Does InMode have any subsidiaries?

The following companies are subsidiares of InMode: Guangzhou InMode Medical Technology Ltd., InMode Asia Limited., InMode India Private Limited, InMode Japan KK, InMode M.D. Ltd., Invasix Corp., Invasix Iberia S.L., Invasix Inc., and Invasix UK Ltd..
Read More

When was InMode founded?

InMode was founded in 2008.

How can I contact InMode?

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The official website for the company is www.inmodemd.com. The healthcare company can be reached via phone at 972-4909-7470 or via email at ir@inmodemd.com.

This page (NASDAQ:INMD) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.